3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
15
Papillomavirus Infections
9
Uterine Cervical Neoplasms
7
Pancreatic Neoplasms
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
4
Neuroendocrine Tumors
3
Neoplasm Metastasis
3
Myasthenia Gravis
3
Multiple Myeloma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Autoimmune Diseases
3
Thyroid Diseases
2
Pancreatic Cyst
2
Neuroblastoma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
COVID-19
2
Brain Neoplasms
2
Abortion, Spontaneous
2
Interventions
Surgical Procedures, Operative
7
Liver Transplantation
5
Lenalidomide
4
Blood Specimen Collection
4
pomalidomide
3
Neoadjuvant Therapy
3
Liquid Biopsy
3
gilteritinib
2
Therapeutics
2
Rituximab
2
Proteasome Inhibitors
2
Observation
2
Mohs Surgery
2
Mitomycin
2
Magnetic Resonance Spectroscopy
2
Immunotherapy, Adoptive
2
Immunoconjugates
2
High-Throughput Nucleotide Sequencing
2
Fluorouracil
2
Drug Therapy
2
DNA, Mitochondrial
2
Brentuximab Vedotin
2
Bendamustine Hydrochloride
2
Antibodies, Monoclonal
2
Antibodies, Bispecific
2
Amplified Fragment Length Polymorphism Analysis
2
trametinib
1
romidepsin
1
nedaplatin
1
lenvatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Recurrence
×
Data Collection
×
Clear all
NCT02262273
2017-03-01
OSCA
AstraZeneca
Completed
2,123 enrolled